1 / 71

RIFAXIMIN IN PROPHYLAXIS AND THERAPY OF DISORDERS OF THE FEMALE REPRODUCTIVE SYSTEM

UTERUS STRUCTURE. PERIMETRIUMOuter serous layer continuous with peritoneum 2. MYOMETRIUMMiddle layer of muscle3. ENDOMETRIUMInnermost layer which provides point of placental attachment and secretions for embryo development. INFLAMMATIONS OF THE UTERUS. METRITIS. ENDOMETRIUMMIOMETRIUMPERIMETRIUM.

tiernan
Download Presentation

RIFAXIMIN IN PROPHYLAXIS AND THERAPY OF DISORDERS OF THE FEMALE REPRODUCTIVE SYSTEM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. RIFAXIMIN IN PROPHYLAXIS AND THERAPY OF DISORDERS OF THE FEMALE REPRODUCTIVE SYSTEM

    2. UTERUS STRUCTURE

    3. INFLAMMATIONS OF THE UTERUS

    4. INFLAMMATIONS OF THE UTERUS

    5. METRITIS

    6. PYOMETRA

    7. ENDOMETRITIS

    8. ENDOMETRITIS

    9. PREDISPOSING CAUSES

    10. ENDOMETRITIS

    11. POSTPARTUM UTERUS CONTAMINANTS

    12. ENDOMETRITIS

    13. IDENTIFYING AN INFECTION

    14. EFFECTS ON FERTILITY

    15. EFFECTS ON FERTILITY

    16. EFFECTS ON FERTILITY

    17. EFFECTS ON FERTILITY

    18. THERAPY IN ENDOMETRITIS

    19. ANTIBIOTIC THERAPY

    20. ANTIBIOTIC THERAPY

    21. ANTIBIOTIC THERAPY

    22. DISINFECTANTS

    23. RESIDUES

    24. HORMONAL THERAPY IN ENDOMETRITIS

    25. RETAINED PLACENTA

    26. RETAINED PLACENTA PREDISPOSING CAUSES

    27. RETAINED PLACENTA

    29. THE ACTIVE SUBSTANCE

    30. RIFAXIMIN MECHANISM OF ACTION

    31. RIFAXIMIN MECHANISM OF ACTION

    32. SPECTRUM OF ACTION

    33. CHEMICAL STRUCTURE

    34. ANTIBACTERIAL ACTIVITY

    35. DOSE ADMINISTERED = ACTIVE DOSE

    36. THERAPEUTIC ACTION AT EVERY POINT IN THE UTERINE CAVITY

    37. THERAPEUTIC ACTION AT EVERY POINT IN THE UTERINE CAVITY

    38. COMPLETE AND UNIFORM DISTRIBUTION TO EVERY POINT IN THE UTERINE CAVITY

    39. COMPLETE AND UNIFORM DISTRIBUTION TO EVERY POINT IN THE UTERINE CAVITY

    40. COMPLETE AND UNIFORM DISTRIBUTION TO EVERY POINT IN THE UTERINE CAVITY

    41. SAFETY

    42. ZERO WITHDRAWAL PERIODS

    43. PACKINGS

    44. FATROXIMIN Purposely studied for intrauterine use

    45. INDICATIONS

    46. POSOLOGY - CATTLE

    47. POSOLOGY - MARE

    48. CLINICAL TRIALS - CATTLE

    49. CLINICAL TRIALS - MARE

    50. INSTRUCTIONS FOR USE

    51. INSTRUCTIONS FOR USE

    52. INSTRUCTIONS FOR USE

    54. THE PESSARY

    55. THE VEHICLE

    56. THE BLISTER PACKAGING

    57. THE GLOVES CONTAINED IN THE PACK

    58. SAFETY

    59. INDICATIONS

    60. INDICATIONS

    61. POSOLOGY COWS and MARES

    62. POSOLOGY SOWS and SMALL RUMINANTS

    63. Prevention of post-partum pathologies of infectious origin in high-risk cows (dystocia or problem parturitions)

    65. Treatment of retained placenta not connected with brucellosis

    66. Treatment of retained placenta not connected with brucellosis

    67. Treatment of postpartum endometritis of infectious origin (C. pyogenes and other pathogens)

    68. Treatment of postpartum endometritis of infectious origin (C. pyogenes and other pathogens)

    69. Treatment of non-specific microbial vulvovaginitis

    70. Treatment of non-specific microbial vulvovaginitis

    71. PACKING

    72. FATROXIMIN Intrauterine Pessaries: TAILOR-MADE THERAPY FOR THE INFECTIONS OF THE FEMELE REPRODUCTIVE SYSTEM

More Related